Connecting science, practice and patient outcomes: Use of BRAF inhibitors for treating metastatic melanoma in clinical practice

Response and resistance with BRAF inhibitors: Mechanisms, markers and unanswered questions

DNA repair inhibitors to overcome drug resistance

Developments in immunotherapy

Combining immunotherapies: inhibiting the CTLA-4 and PD-1 pathways

Drugging the cancer genome to overcome drug resistance

ecancermedicalscience editor's choice for February 2015

Implications of using adjuvant sorafenib and sunitinib in unfavourable renal carcinoma

VEGF targeted therapy and chemo an active combination in rapidly progressive renal cell carcinoma

Tackling renal cancer with a combination of autologous immunotherapy and sunitinib

Efficacy, tolerability and quality of life in metastatic renal cell carcinoma: Welcome and introduction

mRCC: Real-world experience: achieving efficacy beyond clinical trials